Literature DB >> 7474900

Metachromatic leukodystrophy among southern Alaskan Eskimos: molecular and genetic studies.

N M Pastor-Soler1, E M Schertz, M A Rafi, G de Gala, D A Wenger.   

Abstract

Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder resulting from the inability to metabolize sulphatide, an important component of myelin. Although there is significant clinical variability between patients, most have the late-infantile form. It is one of the most common lysosomal disorders involving mental deterioration and is found throughout the world. The great majority of the cases have a deficiency of arylsulphatase A activity. Accurate diagnosis of MLD is complicated by the presence of so-called pseudodeficiency alleles and the need to receive specimens for biochemical testing within 24-48 h of collection. We report the identification of the mutation (a g-to-a transition in the first nucleotide of intron 4) in the arylsulphatase A gene causing late-infantile MLD among the Eskimo population of southern Alaska. As all patients and family members from living and deceased patients had the same mutation, a mutation-based test was developed to identify patients and carriers that can be done on dried blood spots sent via regular mail service. A possible genetic link between this population and the Navajo Indians of the southwestern United States is proposed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7474900     DOI: 10.1007/bf00710424

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  10 in total

1.  Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes.

Authors:  W A SKOOG; W S BECK
Journal:  Blood       Date:  1956-05       Impact factor: 22.113

2.  Leukocyte sonicates as a source for both enzyme assay and DNA amplification for mutational analysis of certain lysosomal disorders.

Authors:  E Louie; M A Rafi; D A Wenger
Journal:  Clin Chim Acta       Date:  1991-05-31       Impact factor: 3.786

3.  Structure of the arylsulfatase A gene.

Authors:  J Kreysing; K von Figura; V Gieselmann
Journal:  Eur J Biochem       Date:  1990-08-17

4.  Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation.

Authors:  W Krivit; E Shapiro; W Kennedy; M Lipton; L Lockman; S Smith; C G Summers; D A Wenger; M Y Tsai; N K Ramsay
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

5.  Improved double-stranded DNA sequencing using the linear polymerase chain reaction.

Authors:  V Murray
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

6.  Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal and N-glycosylation site.

Authors:  V Gieselmann; A Polten; J Kreysing; K von Figura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

7.  Molecular basis of different forms of metachromatic leukodystrophy.

Authors:  A Polten; A L Fluharty; C B Fluharty; J Kappler; K von Figura; V Gieselmann
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

8.  Metachromatic leukodystrophy in the Navajo Indian population: a splice site mutation in intron 4 of the arylsulfatase A gene.

Authors:  N M Pastor-Soler; M A Rafi; J D Hoffman; D Hu; D A Wenger
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

9.  Metachromatic leukodystrophy in the habbanite Jews: high frequency in a genetic isolate and screening for heterozygotes.

Authors:  J Zlotogora; G Bach; Y Barak; E Elian
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

Review 10.  Molecular genetics of metachromatic leukodystrophy.

Authors:  V Gieselmann; J Zlotogora; A Harris; D A Wenger; C P Morris
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

  10 in total
  1 in total

1.  Population carrier rates of pathogenic ARSA gene mutations: is metachromatic leukodystrophy underdiagnosed?

Authors:  Agnieszka Ługowska; Joanna Ponińska; Paweł Krajewski; Grażyna Broda; Rafał Płoski
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.